Peptides by condition · Brain and nerves
Peptides studied for nerve damage (neuropathy)
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 7 study pages on nerve damage (neuropathy): 3 in people (all meta-analyses or randomized trials), and 4 in animals. They studied 3 compounds, with this many study pages each: ARA-290 4, NSI-189 2 and Dihexa 1.
What the research on nerve damage (neuropathy) looks like
Read the design before any result. Of these 7 studies, 4 were in animals and 3 were in people, the largest with 64 people. A finding in cells or animals is where research starts, and many such findings do not hold up in people.
Neuropathy is damage to the nerves outside the brain and spinal cord, felt as burning pain, tingling or numbness, often in the feet and hands. Diabetes is its most common cause. The studies in people here were in sarcoidosis, an inflammatory disease that can destroy the smallest nerve fibers; the rest were in rats and mice with an injured nerve or diabetes.
Studies in people measure symptoms on questionnaires and count small nerve fibers, for example in the clear front of the eye with a special microscope. Animal studies use pain tests after a nerve injury, nerve speed and how well a limb moves again.
Nerve pain responds to placebo, so a placebo group matters. The animal studies used a cut or injured nerve or a diabetes model, which differ from neuropathy that has lasted years in a person.
The 7 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
ARA-290
3 in people · 1 in animalsFor nerve damage (neuropathy), 4 of our study pages are filed under ARA-290: 3 randomized trials in people, and 1 animal study (rats). The largest in people enrolled 64 people and was published in 2017. They were published from 2012 to 2017, in Invest Ophthalmol Vis Sci, Mol Med and Mol Pain.
ARA-290 (cibinetide) has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 64 people · 2017ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg arm
- Randomized trial in people · 22 people · 2012ARA-290 improved small fiber neuropathy symptoms in sarcoidosis
- Randomized trial in people · 2013ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber loss
- Animal study in rats · 2014ARA-290 eased nerve-injury pain for up to 20 weeks in rats
NSI-189
2 in animalsFor nerve damage (neuropathy), 2 of our study pages are filed under NSI-189: 2 animal studies (rats and mice). None of them is in people. They were published from 2019 to 2022, in J Diabetes Res and Diabetes.
NSI-189 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in rats · 2022NSI-189 eased nerve damage and memory problems in diabetic rats
- Animal study in mice · 2019NSI-189 protected nerves and memory in diabetic mice
Dihexa
1 in animalsFor nerve damage (neuropathy), 1 of our study pages is filed under Dihexa: 1 animal study (rats). It was published in 2021, in Ann Med Surg (Lond).
Dihexa has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in rats · 2021Dihexa plus stem cells improved rat motor function after nerve repair
Side by side
For the 3 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg armIt was a small, 28-day trial split across four arms, and only the 4 mg dose clearly beat placebo on the main measure. Nerve fiber counts are stand-in measures for the disease, and the pain result for people with moderate to severe pain came from a subgroup, with P = 0.157.
- ARA-290 improved small fiber neuropathy symptoms in sarcoidosisThis was a small, 4-week pilot trial, and the quality-of-life changes were measured against each patient's starting point rather than against placebo. Pain and fatigue improved no more with ARA-290 than with placebo.
- NSI-189 eased nerve damage and memory problems in diabetic ratsThis was done in rats, so it is not a human result, and it used only one diabetes model. The mitochondrial changes came alongside the nerve and memory gains, which does not show that they caused them.
- NSI-189 protected nerves and memory in diabetic miceThese results come from mouse models of diabetes and rat cells in a dish, not from people with diabetes. Each mouse model used only one sex.
- Dihexa plus stem cells improved rat motor function after nerve repairThis was a small rat study, so it is not a human result. The motor benefit was tied to Dihexa given together with stem cells, and the sensory recovery was pooled across all groups, so Dihexa's effect on its own is not separated out.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for nerve damage (neuropathy)?
Our 7 study pages on nerve damage (neuropathy) are filed under 3 compounds, with this many each: ARA-290 4, NSI-189 2 and Dihexa 1. ARA-290 has the most.
Have any been tested in people with nerve damage (neuropathy)?
Yes: 3 of the 7 were in people, all of them meta-analyses or randomized trials (ARA-290). The largest enrolled 64 people: “ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg arm” (2017).
Is any peptide FDA-approved for nerve damage (neuropathy)?
Not by the labels our status pages read: of the 3 compounds here with an FDA record, none has a use tied to nerve damage (neuropathy).
How large were the studies in people on nerve damage (neuropathy)?
Of the 3 in people, 2 give their size on our pages: 2 had fewer than 100. The largest, a randomized trial from 2017, enrolled 64.
What did the animal and cell studies on nerve damage (neuropathy) use?
4 animal studies (rats and mice), filed under NSI-189, Dihexa and ARA-290. A result in animals or cells shows what to test next, not what happens in a person.
What is the newest study on nerve damage (neuropathy) here?
Of our study pages on nerve damage (neuropathy), the newest is “NSI-189 eased nerve damage and memory problems in diabetic rats”, an animal study in rats published in 2022.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.